Biology

Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy

SOMERSET, N.J. (PRWEB) July 16, 2019 Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA). Through this collaboration,…

Source link

Related posts

Identifying climate-sensitive infectious diseases in animals and humans in Northern regions

Newsemia

The Role of Auxin in the Pattern Formation of the Asteraceae Flower Head (Capitulum)

Newsemia

Scientists find far higher than expected rate of underwater glacial melting

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World